Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution from Idea to IND (I to ITM), today announces that it has entered into two supplemental agreements to the license agreement with Kelun-Biotech in which Kelun-Biotech is entitled to license two ADC products (product 1 and product 2) jointly developed by the two parties to a licensed independent third party. The supplemental agreement shall take effect upon the agreement between Kelun-Biotech and the third party taking effect.
Pursuant to the supplemental agreements, Nona Biosciences is entitled to receive 30% of the proceeds derives from the two products, including:
• Product 1 is a project that Nona Biosciences license Kelun-Biotech to authorize to a third party, and Nona Biosciences is entitled to receive 30% of the upfront payment, milestone payments and tiered royalties.
• The upfront payment of product 1 is US$30 million, and Nona Biosciences is entitled to receive 30% of such payment.
• Product 2 is a project that Nona Biosciences license Kelun-Biotech to co-developed with a third party.
• Nona Biosciences is entitled to receive 30% of the upfront payment, milestone payments and tiered royalties of product 2.
Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed said: “We are glad to achieve in-depth cooperation with Kelun-Biotech which is also a powerful recognition of our proprietary H2L2 platform. Leveraging the Harbour Mice® platform together with our antibody discovery capabilities, we look forward to helping our partners generate differentiated therapeutic molecules more and better on a global basis.”
Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. More information, please check www.nonabio.com